Kratom Testing Expanded to Support Florida's 2026 Requirements

Florida's kratom requirements changed on July 1, 2026. We have updated our T191 Mitragynine Derivatives assay to include three additional analytes:

• 9-hydroxycorynantheidine (9OH)
• 9-fluoro-7-hydroxymitragynine (MGM-16)
• 7-acetoxymitragynine

Before this update, T191 included 7-hydroxymitragynine (7OH), mitragynine pseudoindoxyl (pseudo), and Dihydro-7-hydroxymitragynine (MGM-15). With the three additions, the assay now includes six of the seven compounds named in 2ER26-1. As of August 3, 2026, it does not include 10-hydroxycorynantheidine (10OH) because a suitable reference material is not commercially available at this time.

Florida's current compound limits and ratio

Florida Emergency Rule 2ER26-1 took effect July 1, 2026, and is currently scheduled to expire June 30, 2027. It names seven compounds:

1. 7-hydroxymitragynine
2. 9-hydroxycorynantheidine
3. 10-hydroxycorynantheidine
4. Mitragynine pseudoindoxyl
5. 7-acetoxymitragynine
6. Dihydro-7-hydroxymitragynine (MGM-15)
7. 9-fluoro-7-hydroxymitragynine (MGM-16)

The rule sets a 1 mg/g threshold for solid and powdered products, including encapsulated materials, and a 1 mg/mL threshold for liquid products, including beverages, extracts, and tinctures. Products containing one or more of the listed compounds must have at least 100 parts mitragynine by mass for every one part of the listed compounds, individually or combined.

The operative liquid unit is 1 mg/mL. An initial publication used 1 mg/L, but Florida issued a technical correction on July 1, 2026.

Florida labeling and adulterant requirements

FDACS Emergency Rule 5KER26-9, effective July 1, 2026 and currently scheduled to expire September 29, 2026, requires kratom product labels to disclose the concentrations of the seven compounds and the combined-listed-compounds-to-mitragynine ratio.

The FDACS notice to industry provides a concise official summary of the current labeling and adulterant requirements.

What changed from the former 400 ppm dry-weight framework

Florida's former rules used a 400 ppm (0.04%) dry-weight threshold for 7-OH and required a dry-weight 7-OH label declaration. The official repeal notice states that the Attorney General repealed Emergency Rule 2ER25-3 on June 23, 2026; FDACS records the related 5KER26-8 labeling rule as repealed in its July 1 notice. The former single-analyte framework therefore is not the operative Florida framework after June 30, 2026.

Effective July 1, the 2ER26-1 and 5KER26-9 framework described above replaced that approach with seven listed compounds, product-form reporting units, a mitragynine ratio, and updated labeling requirements.

T191 Testing vs. the T814 Florida Reporting Package

T191 and T814 serve different roles. T191 — Florida Listed Compounds Panel is the LC-MS analytical panel that tests and reports the Florida-listed compounds currently included in the panel, as described above. It supplies the underlying listed-compound analytical data, including individual results, result qualifiers, and applicable method detection limits (MDLs). T191 does not by itself provide the complete calculated Florida labeling package because the required mitragynine information comes from T102.

T814 is a panel/reporting part number, not a third analytical method. It does not independently retest the compounds. T814 combines:

• T102 mitragynine concentration and per-unit results
• T191 Florida-listed-compound results
• Applicable mg/g or mg/mL conversions
• Analyte-specific MDLs and result qualifiers
• Regulated Component Total
• Mitragynine-to-regulated-component Compliance Ratio
• Whole-milligram Alkaloid Ratio Declaration
• The organized table of analytical findings, specifications, calculated labeling values, and applicable PASS/FAIL determinations

For liquid products, an appropriate density result may also be required to convert mass-basis results to mg/mL.

Choosing T191 or T814